Natalizumab - TYSABRI 300 mg, solution à diluer pour perfusion

Business Listing - December 25, 2019

Natalizumab TYSABRI 300 mg, solution à diluer pour perfusion - L04AA23 BIOGEN IDEC LIMITED (ROYAUME-UNI) - 68722564

This is a premium business listing. Stand out from the competition!

List your company and reach more customers today.